ArticleData in brief2025
A comprehensive dataset for understanding immune dynamics in colorectal cancer.
Article in Data in brief, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC), the second most common cause of cancer death in the world, can be divided by the location of the primary tumor in the large intestine: right and left colon, and rectum. Based on the location, CRC shows different molecular characteristics, incidence, pathogenesis, and outcome. Considering the importance of immune components in tumor development, analysis of their interactive relationships with tumor cells in the tumor microenvironment (TME) has received more attention. In addition, routine prognosis systems such as TNM classification have low power to predict the clinical outcome of the disease. Accordingly, the identification of immune-related markers in TME might help to predict the prognosis and clinical outcome of the disease. This research aimed to provide a well-organized histopathological microscopy image dataset for best-scoring CRC. The images were taken from tumor tissue sections of patients with CRC, immunohistochemically stained with antibodies specific for CD3, CD8, CD45RO, PD-1, LAG-3, and Tim3. The markers were separately determined in the tumor's invasive margin and center. The dataset is named CRC-ICM and contains 1,756 images from 136 patients with CRC. It also contains comprehensive information on the clinicopathological characteristics of the patients, with a special focus on the tumor side (right and left). It includes an Excel file describing the patient's demographic, anatomical features, and histopathological grade. The initial version of CRC-ICM is published on the Elsevier Mendeley dataset portal, and the latest version is accessible at: https://databiox.com.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.